NCT00295503 2020-10-20Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant MesotheliomaUniversity of Texas Southwestern Medical CenterPhase 2 Completed53 enrolled 8 charts
NCT01332721 2018-12-05Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is IndicatedTracon Pharmaceuticals Inc.Phase 1 Completed38 enrolled 8 charts
NCT00604461 2017-03-23Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)H. Lee Moffitt Cancer Center and Research InstitutePhase 1/2 Terminated13 enrolled 7 charts